Kymera Therapeutics (NASDAQ:KYMR) Trading Down 5.9% – What’s Next?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price fell 5.9% during trading on Monday . The stock traded as low as $43.79 and last traded at $43.92. 150,689 shares traded hands during trading, a decline of 74% from the average session volume of 579,921 shares. The stock had previously closed at $46.67.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of research analyst reports. Stephens initiated coverage on Kymera Therapeutics in a research note on Monday, November 18th. They issued an “overweight” rating and a $65.00 target price for the company. Oppenheimer raised their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Monday, September 9th. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a report on Friday. They set a “market perform” rating and a $55.00 price objective on the stock. Finally, Morgan Stanley upped their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $53.50.

Kymera Therapeutics Price Performance

The company has a market cap of $2.83 billion, a P/E ratio of -18.53 and a beta of 2.16. The stock’s 50-day moving average price is $46.40 and its 200-day moving average price is $42.64.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the prior year, the business posted ($0.90) EPS. The business’s revenue was down 20.9% compared to the same quarter last year. As a group, analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new stake in Kymera Therapeutics during the third quarter worth $61,000. Quarry LP bought a new stake in shares of Kymera Therapeutics during the 3rd quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares in the last quarter. Comerica Bank boosted its stake in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $139,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.